TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial

TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial

Abstract In this randomized phase II clinical trial, we evaluated the effectiveness of adding the TLR agonists, poly-ICLC or resiquimod, to autologous tumor lysate-pulsed dendritic cell (ATL-DC) vaccination in patients with newly-diagnosed or recurrent WHO Grade III-IV malignant gliomas. The primary...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Richard G. Everson, Willy Hugo, Lu Sun, Joseph Antonios, Alexander Lee, Lizhong Ding, Melissa Bu, Sara Khattab, Carolina Chavez, Emma Billingslea-Yoon, Andres Salazar, Benjamin M. Ellingson, Timothy F. Cloughesy, Linda M. Liau, Robert M. Prins
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Nature Portfolio 2024-05-01
Saila:Nature Communications
Sarrera elektronikoa:https://doi.org/10.1038/s41467-024-48073-y

Internet

https://doi.org/10.1038/s41467-024-48073-y

Antzeko izenburuak